Kinaxis gets new $100 target at National Bank Financial

A better than expected quarter from Kinaxis (Kinaxis Stock Quote, Chart, News: TSX:KXS) has National Bank Financial analyst Richard Tse revisiting his price target on the stock.

Yesterday, Kinaxis reported its Q1, 2017 results. The company earned (U.S.) $3.22-million on revenue of $32.5-million, a topline that was 20 per cent better than the same period last year.

“Our growth continues to be fuelled by expansion of our subscription revenue base, which increased 29 per cent in the first quarter,” said CEO John Sicard. “Global enterprises are turning to Kinaxis to solve their end-to-end supply chain management challenges with concurrent planning, enabling real-time simulation, collaboration and decision-making between previously disconnected teams. Our unique business model, supported by our technologically advanced platform, enable us to deliver consistent, top- and bottom-line growth and robust cash generation.”

Tse says despite the fact that the stock is pricey, investors should stick with Kinaxis because it is a winner. The analyst dug down on why he though the quarter bodes well for the company’s future.

“What’s key is that the important metric of subscription revenue growth continued to consistently drive higher, coming in at 29% year over year,” he said. “With guidance for continued subscription revenue growth of 26% – 28% for 2017, that reinforces our view that the outlook in light of the opportunity even beyond 2017 should continue to drive KXS’s stock price -despite the big run already. As you would expect, our biggest pushback is nearly always valuation. We’re not oblivious to that, but our perspective is that Kinaxis’s small market share of below 5% (around 100 customers) means the growth path is long, which is also why we value the name using a DCF. In our view, the Company continues to take share away from big incumbents like SAP, Oracle and JDA while expanding its base of new customers (65% of revenue in the quarter) while existing ones add to its deployments (2x over three years).”

In a research update to clients today, Tse maintained his “Outperform” rating on Kinaxis, but raised his one-year price target on the stock from $85.00 to $100.00, implying a return of 18 per cent at the time of publication.

Tse thinks Kinaxis will generate EBITDA of (All figures USD) $37.4-million on revenue of $143.6-million in fiscal 2017. He expects these numbers will improve to EBITDA of $46.5-million on a topline of $175.3-million the following year.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kxs
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

11 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

18 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

19 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

20 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago